High-Concentration Lipid Emulsion for Hypotension Without Volume Overload
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lipid emulsions used for treating hypotensive episodes and ischemia/reperfusion injuries suffer from volume overload and fat overload syndromes, and existing treatments do not effectively address organ damage caused by hypotension or ischemia/reperfusion.
Innovation Solution
A lipid emulsion composition comprising at least 20% (w/v) lipid, 1-5% (w/v) emulsifier, 1-5% (w/v) tonicity modifier, 58-88% (w/v) water, and optionally inotrope or compounds like vitamin K or CoQ10, with particle sizes of 200-300 nm, designed to improve tissue redox state and mitochondrial function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional lipid emulsions are administered to treat hypotensive episodes or ischemia-reperfusion injury, then some therapeutic effect is achieved, but volume overload and fat overload syndromes occur
Solution Approach 1:
The patent changes critical parameters of the lipid emulsion formulation, specifically reducing particle size to 0.2-0.5 micrometers (from conventional larger sizes) and adjusting lipid concentration to 10-30% w/v. These parameter modifications allow the emulsion to achieve therapeutic effects while minimizing volume overload and fat overload syndromes by improving circulation dynamics and reducing cumulative fat deposition.
Solution Approach 2:
The patent creates a composite lipid emulsion system combining specific lipid components (triglycerides, phospholipids, cholesterol esters) with carefully selected emulsifiers and tonicity modifiers. This composite formulation optimizes both therapeutic efficacy and safety by ensuring proper emulsion stability, appropriate osmolarity, and reduced risk of overload syndromes.
2Reliability
If higher lipid concentrations are used to improve therapeutic efficacy, then organ injury reduction is enhanced, but volume overload risk increases
Solution Approach 1:
The patent optimizes the lipid concentration parameter to a specific range of 10-30% w/v, which provides sufficient therapeutic effect for organ protection while avoiding excessive volume accumulation. The reduced particle size (0.2-0.5 micrometers) further enables higher concentrations to be administered with reduced volume overload risk, as smaller particles improve circulation and reduce vascular obstruction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces organ injury, improves blood pressure, and decreases the need for vasopressor doses, while minimizing complications such as cardiovascular volume overload and pulmonary edema.
Implementation Method 1
compounds such as vitamin K or CoQ10 that can act as an electron acceptor and thereby improve tissue redox state
Implementation Method 2
improve mitochondrial function and metabolism including oxidative phosphorylation
Implementation Method 3
about 1 to about 5 percent (w/v) emulsifier
Data Source
AI summary
The present disclosure provides lipid emulsions comprising at least 20 percent (w/v) lipid with an average particle size of about 200 to about 300 nm, and use thereof to treat subjects in need of lipid emulsion therapy.